The phase 2b ENLIVEN trial, a multicenter, randomized, double-blind, placebo-controlled study, included 222 patients with biopsy-confirmed NASH and F2-F3 fibrosis, assigned to receive pegozafermin at doses of 15 mg weekly, 30 mg weekly, 44 mg every 2 weeks, or placebo for 24 weeks
Combining GLP-1 weight loss with diet and exercise
These programs may provide: reduced medication costs temporary medication access during financial hardship additional support services Eligibility requirements often depend on income level, insurance status and country of residence
J.HolmesS
Experiment with different injection times to find what works best for your schedule and symptom pattern
In rare cases particularly in people with diabetes and long-term high blood sugars GLP-1 medications can cause blood sugar levels to drop quickly